Lederfolat (Calcium Folinate Pentahydrate)

Calcium folinate supplies a reduced form of folate that bypasses the dihydrofolate reductase block created by certain chemotherapy drugs. By entering the folate cycle downstream, it restores tetrahydrofolate pools, enabling normal DNA synthesis, amino‑acid production, and cell division in tissues affected by folate deficiency or antifolate exposure.

The dosage of Lederfolat is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, age, weight, and the specific indication. Healthcare professionals set the appropriate regimen and adjust it as needed.

Safety data for Lederfolat in pregnancy and lactation are limited. The prescriber should evaluate the potential benefits against any possible risks to the fetus or infant before initiating therapy. Use only if clearly indicated and under medical supervision.

To order Lederfolat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Regular folic acid requires conversion by dihydrofolate reductase to become biologically active, a step blocked by antifolate drugs. Calcium folinate is a reduced folate that bypasses this conversion, making it effective for rescuing patients from antifolate toxicity, whereas standard folic acid does not provide the same protective effect in those situations.

Lederfolat should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Lederfolat is administered orally, typically as a tablet or capsule, and should be taken according to the prescribing clinician’s instructions. It may be taken with or without food, unless the prescriber advises otherwise.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe skin eruptions, significant liver enzyme elevation, hematologic abnormalities like neutropenia or thrombocytopenia, and renal impairment. Patients should be monitored for these events, and therapy should be discontinued if any serious reaction occurs.

Lederfolat is contraindicated in individuals with a known hypersensitivity to calcium folinate or any of its excipients. It should also be used with caution in patients with severe renal or hepatic impairment, and it is not recommended for those who have not been evaluated by a healthcare professional for the indicated uses.